Strongyloidiasis is a parasitic infection that can persist silently in the body for decades, or escalate into a life-threatening condition if the immune system becomes weakened. Understanding how this infection is managed—from standard medications to emerging research—can help patients and healthcare providers work together toward safe and effective care.

Understanding the Goals of Treatment for Strongyloidiasis

The primary aim of treating strongyloidiasis is to completely eliminate the parasite from the body. This is essential because the roundworm Strongyloides stercoralis has a unique ability to reproduce inside the human host through a process called autoinfection, which can lead to lifelong infection if left untreated. Even people who show no symptoms should receive treatment, as the infection can suddenly become dangerous if their immune system weakens due to illness or certain medications.^[4]

Treatment goals vary depending on the stage and severity of the disease. For people with uncomplicated, chronic infection—often discovered incidentally through blood tests or stool examinations—the focus is on eradication of the parasite to prevent future complications. In contrast, patients with hyperinfection syndrome or disseminated strongyloidiasis, where large numbers of larvae invade organs throughout the body, require aggressive treatment combined with intensive supportive care. The death rate in these severe cases can reach 60 to 70 percent, making early detection and prompt treatment critically important.^[7]

Healthcare providers must also consider each patient’s individual circumstances when planning treatment. Factors such as the patient’s immune status, the presence of other medical conditions, whether they are taking medications that suppress the immune system (like corticosteroids), and whether they have a history of travel to or residence in areas where strongyloidiasis is common all influence treatment decisions.^[9]

Because many people remain unaware they are infected for years or even decades, screening programs are particularly important for individuals at risk. This includes anyone who has lived in or traveled to tropical and subtropical regions, especially Southeast Asia, the Western Pacific, parts of Africa, Central and South America, and rural areas of the southern United States. People about to start immunosuppressive therapy, organ transplant recipients, and those with certain infections like human T-lymphotropic virus type 1 (HTLV-1) should all be screened for strongyloidiasis before beginning treatments that could trigger hyperinfection.^[9]

Standard Treatment Approaches: Medications That Target the Parasite

Two medications are currently available in the United States for treating strongyloidiasis, with ivermectin being the preferred first-line therapy. This drug belongs to a class of medications called anthelmintics, which work by paralyzing and killing parasitic worms. Ivermectin is highly effective against adult worms and has become the standard of care in most countries that follow international clinical guidelines.^[6]

For uncomplicated strongyloidiasis, ivermectin is typically given as a single dose of 200 micrograms per kilogram of body weight, taken by mouth. In many cases, this single dose is repeated for one or two days. Some healthcare providers may recommend a second treatment course two weeks after the first to ensure complete eradication of the parasite. The medication works by affecting the nervous system of the worm, causing paralysis and death of the organism.^[9]

The alternative medication is albendazole, which is given at a dose of 400 milligrams twice daily for seven days. Albendazole belongs to the benzimidazole family of drugs and works by disrupting the worm’s ability to absorb glucose, essentially starving the parasite. While effective, albendazole is generally considered less potent than ivermectin for strongyloidiasis and is usually reserved as a second-line option when ivermectin cannot be used.^[9]

In severe cases involving hyperinfection syndrome or disseminated disease, treatment becomes more complex and prolonged. Ivermectin must be given daily at 200 micrograms per kilogram until stool samples and sputum (if lung involvement is present) remain negative for larvae for at least two consecutive weeks. This can mean weeks or even months of continuous therapy. For patients too ill to swallow or absorb oral medications—such as those with intestinal obstruction or severe malabsorption—healthcare providers have successfully used rectal administration of ivermectin. In extremely rare cases where neither oral nor rectal routes are possible, special permission can be obtained from regulatory authorities to use the veterinary subcutaneous formulation of ivermectin.^[9]

An important part of managing severe strongyloidiasis is addressing the underlying immune suppression. If possible, medications that weaken the immune system, particularly corticosteroids, should be reduced or stopped entirely. This allows the patient’s own immune defenses to help fight the infection. However, this decision must be carefully balanced against the risks of stopping these medications for their original indication.^[13]

Side effects of ivermectin are generally mild and may include dizziness, nausea, diarrhea, or fatigue. Albendazole can cause abdominal pain, headache, and in rare cases may affect liver function or blood cell counts. Both medications carry certain precautions: ivermectin should not be used in people who might have a concomitant infection with another parasite called Loa loa (found in parts of Africa), as it can cause severe reactions. Neither medication is recommended during pregnancy, especially in the first trimester, though the risks of untreated strongyloidiasis must be weighed against the risks of treatment.^[9]

After completing treatment, follow-up testing is essential. For patients who had larvae detected in their stool before treatment and who continue to have symptoms, healthcare providers typically perform follow-up stool examinations two to four weeks after treatment ends. If larvae reappear, retreatment is necessary. Some experts also recommend checking antibody levels in the blood six to twelve months after treatment, as successful elimination of the parasite usually leads to declining antibody levels over time.^[13]

Innovations Being Explored in Clinical Research

While the current standard treatments are effective for most cases, researchers continue to explore ways to improve outcomes, particularly for patients with severe disease or those who do not respond to first-line therapy. Several areas of investigation show promise for the future management of strongyloidiasis.

One active area of research involves optimizing ivermectin dosing and treatment duration. Clinical trials are examining whether higher doses or longer courses of ivermectin might achieve better cure rates, especially in immunocompromised patients. Some researchers are investigating combination therapy, using both ivermectin and albendazole together, to determine if attacking the parasite through two different mechanisms might improve treatment success rates. These studies are particularly important for cases where standard single-agent therapy has failed.^[4]

Diagnostic innovation represents another crucial frontier. Researchers are developing more sensitive methods to detect Strongyloides infection, particularly molecular techniques based on polymerase chain reaction (PCR) technology. These DNA-based tests can identify tiny amounts of parasite genetic material in stool, blood, or other body fluids, potentially catching infections that traditional microscopy or antibody tests might miss. Such tools could prove especially valuable for confirming cure after treatment or for screening high-risk populations before they begin immunosuppressive therapy.^[4]

Another promising development involves refining serological tests—blood tests that detect antibodies the body makes against Strongyloides. Current antibody tests can remain positive for months or even years after successful treatment, making it difficult to distinguish active infection from past infection. Researchers are working on high-throughput immunoassays and other advanced techniques that might better correlate with active disease or predict which patients are at highest risk for hyperinfection. These next-generation diagnostics could transform screening programs and treatment monitoring.^[13]

Vaccine development, while still in early conceptual stages, represents a long-term goal for preventing strongyloidiasis. Understanding the parasite’s life cycle and the human immune response to infection has provided researchers with potential targets for vaccine development. However, this work remains at the basic science level, and no vaccine candidates have yet entered human clinical trials.^[3]

Scientists are also investigating the biology of autoinfection—the process by which Strongyloides perpetuates itself within the host. By understanding the molecular signals that trigger larvae to transform into their infectious form inside the intestine, researchers hope to identify new drug targets that could prevent autoinfection and thereby cure chronic infection more reliably. This fundamental research could eventually lead to entirely new classes of antiparasitic medications.^[4]

Clinical trials examining the role of preventive treatment in high-risk populations are ongoing in various parts of the world. These studies investigate whether treating everyone from endemic areas before they start immunosuppressive therapy, regardless of test results, might be safer and more cost-effective than the current strategy of test-and-treat. Such an approach could prevent cases of hyperinfection that occur when diagnostic tests fail to detect infection before dangerous medications are started.^[13]

Most common treatment methods

• Antiparasitic medications (anthelmintics)
  • Ivermectin is the first-line drug, given as a single dose of 200 micrograms per kilogram body weight, usually for one to two days
  • Albendazole is used as an alternative, given as 400 milligrams twice daily for seven days
  • For severe disease (hyperinfection or disseminated infection), ivermectin is given daily until tests remain negative for at least two weeks
  • In patients unable to take oral medication, rectal administration of ivermectin has been used successfully
  • Combination therapy with both ivermectin and albendazole is being studied in research settings
• Immune system management
  • Reduction or discontinuation of immunosuppressive medications, especially corticosteroids, when medically feasible
  • This helps the body’s own immune system fight the infection alongside medication
  • Decision must be carefully individualized based on why the immunosuppressive medication was prescribed
• Supportive care for severe disease
  • Intensive care unit admission may be required for patients with hyperinfection syndrome
  • Treatment of secondary bacterial infections that occur when larvae damage intestinal walls
  • Management of complications such as sepsis, shock, or acute respiratory distress syndrome
  • Antibiotics to treat polymicrobial bacteremia that can occur with disseminated disease
• Follow-up monitoring
  • Stool examinations two to four weeks after treatment in patients who had positive stool tests and persistent symptoms
  • Retreatment if larvae reappear in follow-up testing
  • Serial antibody testing at six and twelve months post-treatment to assess for declining levels
  • Multiple follow-up examinations starting at two weeks for patients who had hyperinfection syndrome
• Preventive screening and treatment
  • Screening before starting corticosteroid therapy or other immunosuppressive medications
  • Testing people with HTLV-1 infection, organ transplant candidates, and those with blood cancers
  • Screening individuals from endemic areas before they begin treatments that weaken immunity
  • Empiric treatment without testing in some high-risk situations, when test results might delay critical care